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Identity 
Other names: BCR1; PHL (Philadelphie) 
HGNC (Hugo): BCR 
Location: 22q11.2 
Local order: Distal to IGL in 22q11.1, proximal to EWS and NF2, both in 22q12. 
 




About 23 exons; 130 kb; 5' centromere - 3' telomere 
orientation. 
Transcription 





130 kDa, 190 kDa; mainly 160 kDa (1271 amino 
acids); N-term ATP binding/Serine-Threonine kinase 
domain, SH2 binding, GTP/GDP exchange domain, 
and C-term domain which functions as a GTPase 
activating protein for p21rac. 











Ubiquitously expressed, with highest expression in 




Protein (serine/threonine) kinase; includes major 
signalisation domains such as: 
- oligomerization domain, responsible of 
homotetramerization of BCR-ABL molecule and 
necessary for its transforming potential; 
- serine threonine kinase domain, including at least 
three SH2 binding sites; able to interact with proteins 
with SH2 domains: These sites include TYR177, 
necessary for binding of Grb2 and activation of RAS 
pathway and beta-isoform of 14-3-3 proteins; 
- GEF domain, in which lies the binding activity to the 
xeroderma pigmentosum protein, involved in DNA 
repair; 
- a COOH-terminal RAC-GAP domain which does not 
participate to hybrid BCR-ABL proteins.  
From the functional point of view, the role of bcr has 
been studied in bcr-null mice which show an increased 
respiratory burst suggesting the involvement of bcr
protein in the regulation of superoxide production, 
probably via RAC.  
In the context of CML, the role of bcr protein has been 
studies in in vitro and in vivo models; bcr gene has 
been shown to be a negative regulator of BCR-ABL. Its 
reduced expression increases the transforming potential 
of BCR-ABL. When overexpressed, bcr blocks BCR-
ABL-mediated transformation in experimental mouse 
models. Serine 354 is required for the inhibitory 
function of bcr over BCR-ABL, as kinase mutants of 
bcr overexpressed in BCR-ABL expressing cells induce 
an increased tumorigenicity. 
Homology 
Drosophila rotund protein; other guanine-nucleotide 










leukemia (CML) --> BCR / ABL 
Disease 
All CML have a t(9;22), at least at the molecular level 
(BCR/ABL); phenotype and stem cell origin: 
multipotent progenitor: t(9;22) is found in all myeloid 
and B- lineage progenitors. 
Prognosis 
The prognosis of CML has changed radically over the 
last 10 years, due to the development of novel drugs 
able to target the enhanced tyrosine kinase activity of 
BCR-ABL. The first of these therapies is Imatinib 
Mesylate (Gleevec) which has become the first line 
therapy for all patients with CML (See ABL and 
CML). In the first cohort trial of patients treated with 
Imatinib mesylate, the rates of complete cytogenetics 
responses (CCR) were exceptionally high (82%) as 
compared to standard IFN-alpha - ARA-C therapy. At 
the most recent 6-year update, the overall survival is 
90% and most interestingly, the rates of progression 
towards more aggressive phases have been found to be 
progressively decreasing in all patients with major 
molecular responses (MMR). (For definition of MMR 
see CML). In IM-resistant or relapsing Ph1+ CML 
patients, second generation tyrosine kinase inhibitor 
(TKI) therapies such as Dasatinib (a dual SRC and 
ABL inhibitor) and Nilotinib have also recently 
become available. 
Cytogenetics 
Anomalies additional to the t(9;22) may be found eith r 
at diagnosis or during course of the disease, or at the 
time of acute transformation; mainly: +der(22), +8, 
i(17q), +19; +21, -Y, -7, -17,+17; variant 
translocations: t(9;22;V) and apparent t(V;22) or 
t(9;V), where V is a variable chromosome, karyotypes 
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Deletion of the derivative chromosome 9: Detected at 
diagnosis (in 10% of patients), probably indiacting a 
genetic instability phenotype, this finding has been 
associated to the more aggressive behavior of the 
disease, a poor prognostic factor potentially reversed by 




72M14 on a case of CML with t(9/22). Note that the probe 
remains on der(22) (Ph) - Courtesy Mariano Rocchi,  






leukemia (ALL) --> BCR / ABL 
Disease 
Most often CD 10+ B-ALL; frequent CNS 
involvement. 
Prognosis 
The prognosis of Ph1+ ALL has changed since the 
introduction of tyrosine-kinase inhibitor therapies, 
especially imatinib mesylate which is currently used as 
a first line therapy associated with either high dose 
chemotherapy or classical ALL-type induction 
(steroids+ vincristine) and maintenance. Allogeneic 
stem cell transplantation is indicated in Ph1+ ALL 
patients relapsing after Imatinib-based regimens. I 
IM-resistant or relapsing Ph1+ ALL patients, second 
generation tyrosine kinase inhibitor (TKI) therapies 
such as Dasatinib (a dual SRC and ABL inhibitor) and 
Nilotinib have also recently become available. 
Cytogenetics 
The chromosome anomaly t(9;22) disappear during 
remission, in contrast with BC-CML cases (CML in 
blast crisis); additional anomalies: +der(22), -7, del(7q) 
most often, +8, but not an i(17q), in contrast with CML 
and AML cases; complex karyotypes, often hyperploid; 
variants and complex translocations may be found as in
CML. 
Hybrid/Mutated gene 
See below. In Both CML and Ph1+ ALL, detection and 
quantification of p210 BCR-ABL and p190 BCR-ABL 






t(9;22)(q34;q11)/acute myeloid leukemia 
(AML) --> BCR / ABL 
Disease 
AML mostly M1 or M2 AML 
Prognosis 
High rates of hematologic, cytogenetic and molecular 
responses have been reported in de novo PH1+ AML, 
which is a rare entity. 
Cytogenetics 
The chromosome anomaly t(9;22) disappear during 
remission, in contrast with BC-CML cases (CML in 
blast crisis); additional anomalies: similar to what is 
found in CML. 
Hybrid/Mutated gene 
BCR/ABL the crucial event lies on der(22), id est 5' 
BCR - 3' ABL hybrid gene is the crucial one, while 
ABL/BCR may or may not be expressed; Breakpoint in 
ABL is variable over a region of 200 kb, often betwen 
the two alternative exons 1b and 1a, sometimes 5' of 1b 
or 3' of 1a, but always 5' of exon 2; breakpoint in BCR 
is either:  
1- in a region called M-bcr (for major breakpoint 
cluster region), a cluster of 5.8 kb, between exons 12 
and 16, also called b1 to b5 of M-bcr; most breakpoints 
being either between b2 and b3, or between b3 and b4; 
transcript is 8.5 kb long; this results in a 210 kDa 
chimeric protein (P210); this is found in (most cases of) 
CML, and in half cases of ALL or AML. 
2- in a 35 kb region between exons 1 and 2, called m-
bcr (minor breakpoint cluster region), -> 7 kb mRNA, 
resulting in a 190 kDa protein (P190) found in 
approximately 25% of adult ALL cases. 
3- A breakpoint in the exon 19 of BCR (designed as the 
micro-bcr) with fusion to abl sequences (a2) has been 
found in neutrophilic CML, with presence of a larger 
protein (P230). 
Abnormal protein 
BCR/ABL P210 comprises the first 902 or 927 amino 
acids from N-term of BCR, whereas P190 BCR and 
P230 include 427 and 1176 aminoacids respectively, 
from the N-term region of BCR; BCR/ABL has a 
cytoplasmic localization, probably by the ability of the 
oligomerization domain to interact with Factin. ABL is 
both nuclear and cytoplasmic, due to the presence of  
nuclear localisation and export signals (NLS and NES) 
within its COOH terminal region. 
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Oncogenesis 
All three forms of BCR-ABL oncogenes have 
transforming potential and it is now clear that they are 
responsible for initiation of the leukemic process 
associated with BCR-ABL oncogenes: Several 
signalling pathways are simultaneously activated an
some phenotypic correlations can be made with the 
molecular abnormalities: 
1- constitutive activation of RAS pathway (via 
TYR177 of the BCR) mimicking the growth-factor-
stimulation of cells, leads to a proliferative behavior; 
2- activation of PI-3K/Akt as well as JAK/STAT 
pathways is most likely responsible for the anti-
apoptotic potential; 
3- BCR/ABL provokes cell adhesive abnormalities (via 
CRK-L, FAK) as well as abnormalities of cell 
migration (via CXCR-4 whose expression is 
downregulated in CML cells expressing high levels of 
BCR-ABL). In experimental settings CD44 has been 
shown to play a major role in homing of BCR-ABL 
expressing cells. Activation of focal adhesion 
molecules (FAK / ) via CRK-L as well as abnormal 
response to SDF-1 leads to adhesive and migratory 
abnormalities of leukemic cells. It should be noted that 
specific signalling events leading to ALL with P190 
and to CML with P210 have not been clearly 
established. A differential activation of Rho protein 
could play a role between the two phenotypes: rho Rac 
and cdc42 interact with BCR-ABL p210 but BCR-ABL 
p190 activates rac and cdc42 only. Deletion of Ikaros, 
has recently been implicated as a major oncogenic 
event cooperating with BCR-ABL in the BCR-ABL+ 
ALL. 
Progression to blast crisis in CML: multiple events 
could be involved, with the major phenotype being a 
genetic instability: 1- mutation of P53, 2- methylation 
of internal ABL promoter; 3- telomere shortening; 4- 
inhibition of negative regulators of BCR-ABL (such as
Abi-1) 5- BCR-ABL induces a major genetic 
instability: molecular pathways involved in this 
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